

Accepted Manuscript

Title: CCP-Score Might Improve the Current Risk Assessment in Newly Diagnosed Prostate Cancer Patients

Author: Marco Oderda, Gabriele Cozzi, Lorenzo Daniele, Anna Sapino, Stefania Munegato, Giuseppe Renne, Ottavio De Cobelli, Paolo Gontero

PII: S0090-4295(16)30914-1

DOI: <http://dx.doi.org/doi: 10.1016/j.urology.2016.11.038>

Reference: URL 20167

To appear in: *Urology*

Received date: 5-4-2016

Accepted date: 22-11-2016

Please cite this article as: Marco Oderda, Gabriele Cozzi, Lorenzo Daniele, Anna Sapino, Stefania Munegato, Giuseppe Renne, Ottavio De Cobelli, Paolo Gontero, CCP-Score Might Improve the Current Risk Assessment in Newly Diagnosed Prostate Cancer Patients, *Urology* (2016), <http://dx.doi.org/doi: 10.1016/j.urology.2016.11.038>.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



TITLE PAGE**TITLE: CCP-SCORE MIGHT IMPROVE THE CURRENT RISK ASSESSMENT IN NEWLY DIAGNOSED PROSTATE CANCER PATIENTS**

AUTHORS: Marco Oderda [1], Gabriele Cozzi [2], Lorenzo Daniele [3], Anna Sapino [3], Stefania Munegato [1], Giuseppe Renne [4], Ottavio De Cobelli [2], Paolo Gontero [1]

AFFILIATIONS:

1] Department of Surgical Sciences, Urology, University of Turin, Turin, Italy

2] Department of Urology, Istituto Europeo di Oncologia, Milan, Italy (IEO)

3] Department of Pathology, Città della Salute e della Scienza, Turin, Italy

4] Department of Pathology, Istituto Europeo di Oncologia, Milan, Italy (IEO)

CORRESPONDING AUTHOR: Paolo Gontero, Associate Professor Department of Surgical Sciences, Urology, University of Turin, Turin, Italy. Phone number: +393478600447. E-mail address: paolo.gontero@unito.it.

WORD COUNT: text 2113; abstract 239.

ABSTRACT**OBJECTIVE**

To assess whether cell-cycle progression (CCP)-score (Prolaris) can improve the current risk assessment in newly diagnosed PCa patients. CCP-score is a well validated prognostic assay predictive of PCa death, biochemical recurrence (BCR) and progression.

METHODS

We evaluated CCP-score at biopsy in 52 patients newly diagnosed with PCa who underwent radical prostatectomy. CCP-score was calculated as average RNA expression of 31 CCP genes, normalized to 15 housekeeping genes. The predictive ability of CCP-score was assessed in univariate and multivariate analyses, and compared to that of Ki-67 levels and traditional clinical variables including PSA, Gleason score, stage, and percentage of positive cores at biopsy.

Download English Version:

<https://daneshyari.com/en/article/5690495>

Download Persian Version:

<https://daneshyari.com/article/5690495>

[Daneshyari.com](https://daneshyari.com)